Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Payables: 2017-2024

Historic Payables for Organogenesis Holdings (ORGO) over the last 8 years, with Dec 2024 value amounting to $28.9 million.

  • Organogenesis Holdings' Payables rose 67.78% to $40.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.5 million, marking a year-over-year increase of 15.09%. This contributed to the annual value of $28.9 million for FY2024, which is 5.90% down from last year.
  • Organogenesis Holdings' Payables amounted to $28.9 million in FY2024, which was down 5.90% from $30.7 million recorded in FY2023.
  • In the past 5 years, Organogenesis Holdings' Payables registered a high of $32.3 million during FY2022, and its lowest value of $23.4 million during FY2020.
  • For the 3-year period, Organogenesis Holdings' Payables averaged around $30.7 million, with its median value being $30.7 million (2023).
  • As far as peak fluctuations go, Organogenesis Holdings' Payables fell by 17.63% in 2020, and later climbed by 25.48% in 2021.
  • Organogenesis Holdings' Payables (Yearly) stood at $23.4 million in 2020, then rose by 25.48% to $29.3 million in 2021, then climbed by 10.19% to $32.3 million in 2022, then fell by 4.97% to $30.7 million in 2023, then fell by 5.90% to $28.9 million in 2024.